Maria A Karalexi1, Marios K Georgakis2, Nikolaos G Dimitriou2, Theodoros Vichos2, Andreas Katsimpris2, Eleni Th Petridou3, Fotios C Papadopoulos4. 1. Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Neuroscience, Psychiatry, Uppsala University, Uppsala University Hospital, Uppsala, Sweden. 2. Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 3. Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Unit of Clinical Epidemiology, Karolinska Institute, Stockholm, Sweden. 4. Department of Neuroscience, Psychiatry, Uppsala University, Uppsala University Hospital, Uppsala, Sweden. Electronic address: fotis.papadopoulos@neuro.uu.se.
Abstract
BACKGROUND: Previous studies have examined whether steroid hormone treatment in transgender individuals may affect cognitive function; yet, their limited power does not allow firm conclusions to be drawn. We leveraged data from to-date literature aiming to explore the effect of gender-affirming hormone administration on cognitive function in transgender individuals. METHODS: A search strategy of MEDLINE was developed (through June 1, 2019) using the key terms transgender, hormone therapy and cognitive function. Eligible were (i) cohort studies examining the longitudinal effect of hormone therapy on cognition, and (ii) cross-sectional studies comparing the cognitive function between treated and non-treated individuals. Standardized mean differences (Hedges' g) were pooled using random-effects models. Study quality was evaluated using the Newcastle-Ottawa Scale. OUTCOMES: Ten studies (seven cohort and three cross-sectional) were eligible representing 234 birth-assigned males (aM) and 150 birth-assigned females (aF). The synthesis of cohort studies (n = 5) for visuospatial ability following hormone treatment showed a statistically significant enhancement among aF (g = 0.55, 95% confidence intervals [CI]: 0.29, 0.82) and an improvement with a trend towards statistical significance among aM (g = 0.28, 95%CI: -0.01, 0.58). By contrast, no adverse effects of hormone administration were shown. No heterogeneity was evident in most meta-analyses. INTERPRETATION: Current evidence does not support an adverse impact of hormone therapy on cognitive function, whereas a statistically significant enhancing effect on visuospatial ability was shown in aF. New longitudinal studies with longer follow-up should explore the long-term effects of hormone therapy, especially the effects on younger individuals, where there is greater scarcity of data.
BACKGROUND: Previous studies have examined whether steroid hormone treatment in transgender individuals may affect cognitive function; yet, their limited power does not allow firm conclusions to be drawn. We leveraged data from to-date literature aiming to explore the effect of gender-affirming hormone administration on cognitive function in transgender individuals. METHODS: A search strategy of MEDLINE was developed (through June 1, 2019) using the key terms transgender, hormone therapy and cognitive function. Eligible were (i) cohort studies examining the longitudinal effect of hormone therapy on cognition, and (ii) cross-sectional studies comparing the cognitive function between treated and non-treated individuals. Standardized mean differences (Hedges' g) were pooled using random-effects models. Study quality was evaluated using the Newcastle-Ottawa Scale. OUTCOMES: Ten studies (seven cohort and three cross-sectional) were eligible representing 234 birth-assigned males (aM) and 150 birth-assigned females (aF). The synthesis of cohort studies (n = 5) for visuospatial ability following hormone treatment showed a statistically significant enhancement among aF (g = 0.55, 95% confidence intervals [CI]: 0.29, 0.82) and an improvement with a trend towards statistical significance among aM (g = 0.28, 95%CI: -0.01, 0.58). By contrast, no adverse effects of hormone administration were shown. No heterogeneity was evident in most meta-analyses. INTERPRETATION: Current evidence does not support an adverse impact of hormone therapy on cognitive function, whereas a statistically significant enhancing effect on visuospatial ability was shown in aF. New longitudinal studies with longer follow-up should explore the long-term effects of hormone therapy, especially the effects on younger individuals, where there is greater scarcity of data.
Authors: Blair R Hamilton; Giscard Lima; James Barrett; Leighton Seal; Alexander Kolliari-Turner; Guan Wang; Antonia Karanikolou; Xavier Bigard; Herbert Löllgen; Petra Zupet; Anca Ionescu; Andre Debruyne; Nigel Jones; Karin Vonbank; Federica Fagnani; Chiara Fossati; Maurizio Casasco; Demitri Constantinou; Bernd Wolfarth; David Niederseer; Andrew Bosch; Borja Muniz-Pardos; José Antonio Casajus; Christian Schneider; Sigmund Loland; Michele Verroken; Pedro Manonelles Marqueta; Francisco Arroyo; André Pedrinelli; Konstantinos Natsis; Evert Verhagen; William O Roberts; José Kawazoe Lazzoli; Rogerio Friedman; Ali Erdogan; Ana V Cintron; Shu-Hang Patrick Yung; Dina C Janse van Rensburg; Dimakatso A Ramagole; Sandra Rozenstoka; Felix Drummond; Theodora Papadopoulou; Paulette Y O Kumi; Richard Twycross-Lewis; Joanna Harper; Vasileios Skiadas; Jonathan Shurlock; Kumpei Tanisawa; Jane Seto; Kathryn North; Siddhartha S Angadi; Maria Jose Martinez-Patiño; Mats Borjesson; Luigi Di Luigi; Michiko Dohi; Jeroen Swart; James Lee John Bilzon; Victoriya Badtieva; Irina Zelenkova; Juergen M Steinacker; Norbert Bachl; Fabio Pigozzi; Michael Geistlinger; Dimitrios G Goulis; Fergus Guppy; Nick Webborn; Bulent O Yildiz; Mike Miller; Patrick Singleton; Yannis P Pitsiladis Journal: Sports Med Date: 2021-03-24 Impact factor: 11.928
Authors: Steven Jett; Niharika Malviya; Eva Schelbaum; Grace Jang; Eva Jahan; Katherine Clancy; Hollie Hristov; Silky Pahlajani; Kellyann Niotis; Susan Loeb-Zeitlin; Yelena Havryliuk; Richard Isaacson; Roberta Diaz Brinton; Lisa Mosconi Journal: Front Aging Neurosci Date: 2022-03-09 Impact factor: 5.750
Authors: Michele A O'Connell; Thomas P Nguyen; Astrid Ahler; S Rachel Skinner; Ken C Pang Journal: J Clin Endocrinol Metab Date: 2022-01-01 Impact factor: 5.958